[go: up one dir, main page]

NO20023163L - Fremgangsmåter for deteksjon av amyloidogene proteiner - Google Patents

Fremgangsmåter for deteksjon av amyloidogene proteiner

Info

Publication number
NO20023163L
NO20023163L NO20023163A NO20023163A NO20023163L NO 20023163 L NO20023163 L NO 20023163L NO 20023163 A NO20023163 A NO 20023163A NO 20023163 A NO20023163 A NO 20023163A NO 20023163 L NO20023163 L NO 20023163L
Authority
NO
Norway
Prior art keywords
aggregation
assay
amyloid
peptide
amyloid peptide
Prior art date
Application number
NO20023163A
Other languages
English (en)
Norwegian (no)
Other versions
NO20023163D0 (no
Inventor
Girija Krishnamurthy
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of NO20023163D0 publication Critical patent/NO20023163D0/no
Publication of NO20023163L publication Critical patent/NO20023163L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
NO20023163A 1999-12-29 2002-06-28 Fremgangsmåter for deteksjon av amyloidogene proteiner NO20023163L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/474,970 US6399314B1 (en) 1999-12-29 1999-12-29 Methods of detection of amyloidogenic proteins
PCT/US2000/032693 WO2001050134A2 (en) 1999-12-29 2000-12-01 Methods of detection of amyloidogenic proteins

Publications (2)

Publication Number Publication Date
NO20023163D0 NO20023163D0 (no) 2002-06-28
NO20023163L true NO20023163L (no) 2002-08-27

Family

ID=23885720

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023163A NO20023163L (no) 1999-12-29 2002-06-28 Fremgangsmåter for deteksjon av amyloidogene proteiner

Country Status (21)

Country Link
US (1) US6399314B1 (xx)
EP (1) EP1242822B1 (xx)
JP (1) JP2003519383A (xx)
KR (1) KR20020070470A (xx)
CN (1) CN1211661C (xx)
AT (1) ATE399323T1 (xx)
AU (1) AU774377B2 (xx)
BR (1) BR0016883A (xx)
CA (1) CA2395789C (xx)
DE (1) DE60039310D1 (xx)
DK (1) DK1242822T3 (xx)
EA (1) EA005582B1 (xx)
ES (1) ES2309003T3 (xx)
HK (1) HK1046550B (xx)
IL (2) IL150080A0 (xx)
MX (1) MXPA02006362A (xx)
NO (1) NO20023163L (xx)
NZ (1) NZ519612A (xx)
PL (1) PL356813A1 (xx)
PT (1) PT1242822E (xx)
WO (1) WO2001050134A2 (xx)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
DE19923811C1 (de) * 1999-05-20 2000-12-07 Robert Koch Inst Verfahren zur Diagnose TSE-induzierter Veränderungen in Geweben mittels Infrarotspektroskopie
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6689753B1 (en) * 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
EP2151187A1 (en) 2000-08-21 2010-02-10 The General Hospital Corporation Methods for diagnosing a neurodegenerative condition
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
EP2298361A3 (en) * 2001-04-27 2011-05-04 The General Hospital Corporation Ocular diagnosis of Alzheimer's disease
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
EP1395833B1 (en) * 2001-05-31 2013-02-27 Adlyfe, Inc. Misfolded protein sensor method
US20060057107A1 (en) * 2001-12-21 2006-03-16 Shaked Ze Ev Combination treatment for multiple sclerosis
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US20050048539A1 (en) * 2003-06-13 2005-03-03 The General Hospital Corporation Methods to monitor molecule conformation and molecule/molecule proximity
SE0401219D0 (sv) * 2004-05-10 2004-05-10 Biochromix Ab Metoder för detektera konformationsförändringar eller aggregering hos proteiner med hjälp av konjugerade polyelektrolyter
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
ES2434732T3 (es) 2004-12-15 2013-12-17 Janssen Alzheimer Immunotherapy Anticuerpos para beta-amiloide humanizados para su uso en mejorar la cognición
ES2396555T3 (es) * 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
JP4568840B2 (ja) * 2004-12-28 2010-10-27 国立大学法人金沢大学 アルツハイマー病の検査方法
WO2006069697A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Colorimetrically assessing peptide characteristics
AU2006214463B2 (en) * 2005-02-15 2012-08-30 Presympto, Inc. Method for detecting misfolded proteins and prions
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
EP2386861A3 (en) * 2005-07-13 2012-07-18 Crossbeta Biosciences B.V. Cross-ß structure binding compounds
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
BRPI0613525A2 (pt) * 2005-07-13 2011-05-31 Crossbeta Biosciences Bv métodos para produzir uma composição imunogênica, para melhorar a imunogenicidade de uma composição, para intensificar a imunogenicidade de uma composição de vacina, e para determinar a quantidade de estruturas beta-cruzadas em uma composição de vacina, usos de estruturas beta-cruzadas, e de uma composição imunogênica, vacina de subunidade, e, composição imunogênica
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
AU2007277186B2 (en) * 2006-07-28 2014-01-30 Presympto, Inc. Peptide probes for diagnostics and therapeutics
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2058000A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Immunogenic compositions capable of activating T cells
EP2058001A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
US20100021390A1 (en) * 2008-03-17 2010-01-28 The Research Foundation Of State University Of New York Fluorescent Analogs Of The Islet Amyloid Polypeptide
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
RU2509155C1 (ru) * 2012-10-25 2014-03-10 Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
GB201303507D0 (en) * 2013-02-27 2013-04-10 Hollfelder Florian Assays
US9588129B2 (en) * 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
CN104803993B (zh) * 2015-03-01 2017-11-03 四川大学 一种具有Aβ亲和力的荧光化合物及其用途
CN105651752B (zh) * 2016-02-26 2019-04-12 国家纳米科学中心 淀粉样蛋白的检测方法
CN105717182B (zh) * 2016-03-10 2018-05-11 中南大学 一种用于同步检测淀粉样多肽单体和聚集体的生物传感器及其构建方法和应用
WO2018136910A1 (en) * 2017-01-23 2018-07-26 Rensselaer Polytechnic Institute Systems and methods for binding amyloid fibrils using fluorescent protein
CN108489941B (zh) * 2018-01-31 2021-07-27 吉林大学 溴酚蓝在作为检测牛胰岛素淀粉样纤维探针和作为牛胰岛素淀粉样纤维抑制剂方面的应用
US20210165001A1 (en) * 2018-08-03 2021-06-03 The University Of Hong Kong Compositions and methods for detection and imaging of amyloid fibrils, amyloid plaques, rna, and nucleoli
CA3120066A1 (en) 2018-11-14 2020-05-22 University Of Kentucky Research Foundation Diagnosis of diabetes by detecting aggregated amylin in erythrocytes
CN111504957B (zh) * 2019-01-31 2021-12-03 吉林大学 一种维多利亚蓝b及其衍生物在制备异构化蛋白的探针或抑制剂中的应用
KR102258048B1 (ko) * 2019-05-30 2021-05-31 주식회사 캔티스 아밀로이드 베타 올리고머의 검출 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2013396A1 (en) * 1989-04-05 1990-10-05 Dennis J. Selkoe Diagnostic method for alzheimer's disease: examination of non-neural tissue
US5276059A (en) 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
CA2242851A1 (en) 1995-08-17 1997-02-27 The Ontario Cancer Institute Protein fibril assembly assay
JPH0995444A (ja) * 1995-10-02 1997-04-08 Teijin Ltd アミロイド蛋白凝集阻害剤
EP1003539A4 (en) 1997-08-14 2002-09-11 Univ California AMYLOID beta-FLUORESCENT PEPTIDES AND USE THEREOF
JP4537577B2 (ja) * 1998-03-13 2010-09-01 ユニバーシティ・オブ・ワシントン アルツハイマー病及びプリオン病の治療に関する抗プラーク療法を特定するコンゴ好染性マルタ十字形アミロイドプラークのｉｎｖｉｔｒｏにおける形成

Also Published As

Publication number Publication date
IL150080A0 (en) 2002-12-01
DE60039310D1 (de) 2008-08-07
EP1242822B1 (en) 2008-06-25
CA2395789C (en) 2010-03-30
AU774377B2 (en) 2004-06-24
AU1810301A (en) 2001-07-16
KR20020070470A (ko) 2002-09-09
NO20023163D0 (no) 2002-06-28
NZ519612A (en) 2004-04-30
HK1046550B (zh) 2008-12-19
EP1242822A2 (en) 2002-09-25
US6399314B1 (en) 2002-06-04
EA005582B1 (ru) 2005-04-28
IL150080A (en) 2009-02-11
MXPA02006362A (es) 2002-11-29
JP2003519383A (ja) 2003-06-17
CN1415074A (zh) 2003-04-30
DK1242822T3 (da) 2008-09-29
BR0016883A (pt) 2002-10-01
PL356813A1 (en) 2004-07-12
EA200200722A1 (ru) 2002-12-26
ES2309003T3 (es) 2008-12-16
HK1046550A1 (en) 2003-01-17
ATE399323T1 (de) 2008-07-15
WO2001050134A3 (en) 2002-06-27
PT1242822E (pt) 2008-09-29
CN1211661C (zh) 2005-07-20
CA2395789A1 (en) 2001-07-12
WO2001050134A2 (en) 2001-07-12

Similar Documents

Publication Publication Date Title
NO20023163D0 (no) Fremgangsmåter for deteksjon av amyloidogene proteiner
DK0679251T3 (da) Fremgangsmåde og apparat til vurdering af biopolymerers fitness
EP1664783A4 (en) QUICK TEST FOR GLYCED ALBUMIN
PH12020551371A1 (en) Assays to detect neurodegeneration
TW200632320A (en) Methods of in vitro analysis using time-domain nmr spectroscopy
Yin et al. A two-input fluorescent logic gate for glutamate and zinc
Strucksberg et al. Proteasomal activity in skeletal muscle: a matter of assay design, muscle type, and age
Zinellu et al. Highly sensitive simultaneous detection of cultured cellular thiols by laser induced fluorescence‐capillary electrophoresis
CN106544007A (zh) 一种检测生物体系内次氯酸的荧光探针及其应用
ES2898929T3 (es) Diagnóstico y tratamiento de alfa-sinucleinopatías
JPH01210863A (ja) 精子細胞計数および生存精子細胞の比率、あるいは、これらいずれか一方の高速定量方法ならびにその装置
WO2023234979A3 (en) High field magnetometry with hyperpolarized nuclear spins
DE50214753D1 (de) Vorrichtung zur bestimmung rheologischer eigenschaften
FR2894675B1 (fr) Distinction des meningites bacteriennes et virales
Luo et al. Discrimination of wet or dried arterial and venous blood for forensic applications via eosin fluorescence lifetime
Flemmig et al. Rapid and reliable determination of the halogenating peroxidase activity in blood samples
CA2586654A1 (en) Use of asc as a marker for colorectal cancer
ATE466285T1 (de) Diagnose von leberzirrhose mittels eines für menschliches protoonkogenes protein spezifischen antikörpers
DE602004021193D1 (de) Erstellung von digitalaufnahmen einzelner radialer immundiffusionstests
CN110441457A (zh) 一种检测尿液中同型半胱氨酸的方法
DE60324820D1 (de) Verfahren zum testen des oxidiertes-ldl-beta-2-glycoprotein-i-komplexes in vivo
RU2008132559A (ru) Способ оценки агрегационной способности эритроцитов
IT201900002585A1 (it) Sistema, metodo e dispositivo per la rilevazione di tannini in un liquido
RU2315998C2 (ru) Способ определения влияния соединений на процесс скачка митохондриальной проницаемости и мембранный потенциал митохондрий
Hirai et al. 3-Nitrotyrosine shortens axons of non-dopaminergic neurons by inhibiting mitochondrial motility

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application